Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on April 23, 2007, primarily to report its financial results for the first quarter of 2007. The press release, attached as Exhibit 99.1, details the company's performance during the period. Investors should note that while the entire press release is furnished, certain sections, specifically the first two paragraphs and pages 6-10, are deemed "filed" and thus subject to greater regulatory scrutiny under the Exchange Act. This filing serves as the official communication channel for EW's Q1 2007 earnings. While the 8-K itself doesn't contain the specific financial figures, it directs investors to the accompanying press release for that crucial information. The CFO, Thomas M. Abate, signed off on the report, indicating the accuracy and official nature of the disseminated financial data.
Key Highlights
- 1Edwards Lifesciences reported its first quarter 2007 financial results on April 23, 2007.
- 2The results were disclosed via a press release, filed as Exhibit 99.1 to the 8-K.
- 3The filing indicates that specific portions of the press release (first two paragraphs and pages 6-10) are considered "filed" under the Exchange Act.
- 4The press release contains detailed financial results for the first quarter of 2007.
- 5The report was signed by Thomas M. Abate, Corporate Vice President, Chief Financial Officer and Treasurer.
- 6No other significant business events or material changes were reported in this specific 8-K filing.
- 7The filing is a standard procedure for timely disclosure of quarterly financial performance.